www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

USEUROPEAFRICAASIA 中文雙語Fran?ais
Home / World

Trials of cancer drug show potential

By Reuters in Madrid | China Daily | Updated: 2014-09-29 07:36

A new breast cancer drug from Roche has shown "unprecedented" survival benefits in a clinical trial, boosting prospects for its widespread use in women with an aggressive form of the disease.

Patients with a type of breast cancer known as HER-2 positive, which makes up about a quarter of all breast cancers, who were given Perjeta on top of older medicine Herceptin and chemotherapy lived 15.7 months longer than those on Herceptin and chemotherapy alone.

"The survival improvement of nearly 16 months ... is unprecedented among studies of metastatic breast cancer," lead researcher Sandra Swain from the Washington Hospital Center told the European Society for Medical Oncology annual congress on Sunday.

Perjeta, which was approved by regulators two years ago, was tested in the Roche-backed study in more than 800 women with metastatic disease, whose breast cancer had spread to other parts of the body.

Researchers had previously reported that the Perjeta drug regimen significantly extended progression-free survival, or the period of time patients live without their disease worsening, but the final overall survival data has taken longer to collect.

The median overall survival time was 56.5 months for those given Perjeta against 40.8 months for patients taking only the older drugs.

Remarkable results

Javier Cortes, another researcher on the study from the Vall D'Hebron Institute of Oncology in Barcelona, said the results were "remarkable" and suggested using Perjeta should be the standard of care for HER-2 positive breast cancer patients.

A favorable reaction from oncologists will underpin expectations of strong sales for Perjeta, which analysts currently expect to sell $3.1 billion a year by 2018, according to consensus forecasts compiled by Thomson Reuters Cortellis.

But it poses a challenge for healthcare providers since Perjeta is a costly drug and the multiple-drug regimen promises to strain budgets.

For Roche, Perjeta is an important new product that should help defend its position in breast cancer, following the success of Herceptin, which was first approved in 1998.

The company said the latest data will be submitted to regulatory authorities around the world for inclusion in the prescribing information for Perjeta.

(China Daily 09/29/2014 page10)

Today's Top News

Editor's picks

Most Viewed

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 国产一区二区三区精品久久呦 | 国产日产高清欧美一区二区三区 | 国产成人精品免费视频大全软件 | 国产精品亚洲专一区二区三区 | 伊人婷婷色香五月综合缴激情 | 亚洲欧美日韩中文字幕在线 | 114一级毛片免费观看 | 成人小视频在线观看免费 | 欧美精品99 | 久久香蕉国产线看观看式 | 国产伦精品一区二区三区无广告 | 久久久久亚洲香蕉网 | 青青自拍视频一区二区三区 | 国产在线精品一区二区 | 国产一精品一aⅴ一免费 | 欧美日韩免费一区二区在线观看 | 两性免费视频 | 国产视频中文字幕 | 亚洲最大看欧美片网站 | 国产高清亚洲 | 亚洲 欧美 精品 中文第三 | 欧美肥婆videoxxx | 黄色作爱视频 | 国产大片中文字幕在线观看 | 男女免费爽爽爽在线视频 | 99久久精品久久久久久清纯 | 亚洲欧洲日产国产 最新 | 手机看片99 | 欧美日韩视频免费播放 | 日本精高清区一 | 一区二区三区在线播放 | 另类专区另类专区亚洲 | 黄大片日本一级在线a | 黄+色+性+人免费 | 国产成人久久 | 欧美高清正版在线 | 成年男女男精品免费视频网站 | 国产成人精品免费视频大 | 91视频天堂 | 特级无码a级毛片特黄 | 在线播放亚洲美女视频网站 |